<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Catarata &#187; fármacos oculares</title>
	<atom:link href="https://temas.sld.cu/catarata/tag/farmacos-oculares/feed/" rel="self" type="application/rss+xml" />
	<link>https://temas.sld.cu/catarata</link>
	<description>Sitio web de la red de salud de Cuba sobre catarata en oftalmología</description>
	<lastBuildDate>Wed, 01 Apr 2026 09:47:19 +0000</lastBuildDate>
	<language>es-ES</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
	<item>
		<title>Budget impact model of Mydrane®, a new intracameral injectable used for intra-operative mydriasis, from a UK hospital perspective</title>
		<link>https://temas.sld.cu/catarata/2018/10/23/budget-impact-model-of-mydrane-a-new-intracameral-injectable-used-for-intra-operative-mydriasis-from-a-uk-hospital-perspective/</link>
		<comments>https://temas.sld.cu/catarata/2018/10/23/budget-impact-model-of-mydrane-a-new-intracameral-injectable-used-for-intra-operative-mydriasis-from-a-uk-hospital-perspective/#comments</comments>
		<pubDate>Tue, 23 Oct 2018 17:51:59 +0000</pubDate>
		<dc:creator><![CDATA[catarata]]></dc:creator>
				<category><![CDATA[Actualizaciones]]></category>
		<category><![CDATA[fármacos oculares]]></category>

		<guid isPermaLink="false">http://articulos.sld.cu/catarata/?p=2206</guid>
		<description><![CDATA[Mydrane® es una nueva solución intracameral inyectable que contiene dos midriáticos (tropicamida 0.02% y fenilefrina 0.31%) y un anestésico (lidocaína 1%) elaborada y aprobada para uso exclusivo intracameral.   Este estudio estimó el impacto del presupuesto durante un año utilizando Mydrane® en lugar de gotas oculares de dilatación tópica, para un hospital del Reino Unido [&#8230;]]]></description>
		<wfw:commentRss>https://temas.sld.cu/catarata/2018/10/23/budget-impact-model-of-mydrane-a-new-intracameral-injectable-used-for-intra-operative-mydriasis-from-a-uk-hospital-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery</title>
		<link>https://temas.sld.cu/catarata/2018/06/01/visual-outcomes-efficacy-and-surgical-complications-associated-with-intracameral-phenylephrine-1-0ketorolac-0-3-administered-during-cataract-surgery/</link>
		<comments>https://temas.sld.cu/catarata/2018/06/01/visual-outcomes-efficacy-and-surgical-complications-associated-with-intracameral-phenylephrine-1-0ketorolac-0-3-administered-during-cataract-surgery/#comments</comments>
		<pubDate>Fri, 01 Jun 2018 10:02:36 +0000</pubDate>
		<dc:creator><![CDATA[catarata]]></dc:creator>
				<category><![CDATA[Actualizaciones]]></category>
		<category><![CDATA[fármacos oculares]]></category>

		<guid isPermaLink="false">http://articulos.sld.cu/catarata/?p=2153</guid>
		<description><![CDATA[En este estudio, al comparar los resultados visuales, el tiempo quirúrgico y las complicaciones quirúrgicas perioperatorias después del uso intracameral de fenilefrina 1.0% / ketorolaco 0.3% (F/K) o epinefrina (Epi) durante la cirugía de cataratas, se obtuvieron como resultados que el uso intracameral de F/K puede ser efectivo para mantener la midriasis intraoperatoria. Incluso, parece [&#8230;]]]></description>
		<wfw:commentRss>https://temas.sld.cu/catarata/2018/06/01/visual-outcomes-efficacy-and-surgical-complications-associated-with-intracameral-phenylephrine-1-0ketorolac-0-3-administered-during-cataract-surgery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
